Oncology

At Ipsen, we are committed to driving innovation and fostering solutions for the most difficult-to-treat cancers. By focusing on areas of oncology with the highest unmet needs, we seek to improve the lives of people living with cancer, delivering the outcomes which matter most to patients.

Our Commitment to Oncology

Ipsen’s oncology franchise is key to the success of our business. Our strategy is to be a leader in treating solid and blood tumors in patient populations with high unmet medical needs.

Working with and for patients guides our strategy. Patients and their families inspire and drive us to tackle some of the hardest-to-treat cancers where we can have a direct impact for those who need treatment the most. That’s why we actively listen to and learn from their experiences, integrating their insights into our efforts, from early research through development.

We also work closely with patient groups to understand the factors that play a role in improving a patient’s quality of life. Through these collaborations we look to co-create solutions that effectively support patients.

By focusing on selected cancers and working with like-minded partners, we are fostering solutions, advancing science and delivering new, innovative treatments with the patient at the center of everything we do.

Our Areas of Expertise

Our oncology expertise focuses on solid and blood tumors with high unmet medical needs in patient populations that are currently not well supported.

Our Oncology Pipeline

At Ipsen, we believe that great partnerships create great possibilities. A culture of external innovation drives our research, development and commercialization. We identify, develop and integrate innovative products that are a strategic fit for our portfolio and that deliver value for patients. With like-minded partners, our goal is to foster solutions, advance science and deliver new therapies.

Ipsen has built its strength in oncology through solid long-term partnerships which are fast-tracking new approaches to target hard-to-treat cancers that are often overlooked as research targets.

Over the next few years, we will continue to build our high value and sustainable pipeline. We are seeking collaborations with companies who are advancing approved products, investigational assets or a novel preclinical approach in both solid tumors and blood cancers, including niche tumors and broader populations with a biomarker segmentation.

Learn more about our pipeline
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021